Below are the most recent publications written about "Toll-Like Receptor 2" by people in Profiles.
-
Dombkowski AA, Cukovic D, Bagla S, Jones M, Caruso JA, Chugani HT, Chugani DC. TLR7 activation in epilepsy of tuberous sclerosis complex. Inflamm Res. 2019 Dec; 68(12):993-998.
-
Andrade-Silva M, Cenedeze MA, Perandini LA, Felizardo RJF, Watanabe IKM, Agudelo JSH, Castoldi A, Gon?alves GM, Origassa CST, Semedo P, Hiyane MI, Foresto-Neto O, Malheiros DMAC, Reis MA, Fujihara CK, Zatz R, Pacheco-Silva A, C?mara NOS, de Almeida DC. TLR2 and TLR4 play opposite role in autophagy associated with cisplatin-induced acute kidney injury. Clin Sci (Lond). 2018 08 31; 132(16):1725-1739.
-
Roedig H, Nastase MV, Frey H, Moreth K, Zeng-Brouwers J, Poluzzi C, Hsieh LT, Brandts C, Fulda S, Wygrecka M, Schaefer L. Biglycan is a new high-affinity ligand for CD14 in macrophages. Matrix Biol. 2019 04; 77:4-22.
-
Frey H, Moreth K, Hsieh LT, Zeng-Brouwers J, Rathkolb B, Fuchs H, Gailus-Durner V, Iozzo RV, de Angelis MH, Schaefer L. A novel biological function of soluble biglycan: Induction of erythropoietin production and polycythemia. Glycoconj J. 2017 06; 34(3):393-404.
-
Humann J, Mann B, Gao G, Moresco P, Ramahi J, Loh LN, Farr A, Hu Y, Durick-Eder K, Fillon SA, Smeyne RJ, Tuomanen EI. Bacterial Peptidoglycan Traverses the Placenta to Induce Fetal Neuroproliferation and Aberrant Postnatal Behavior Cell Host Microbe. 2016 03 09; 19(3):388-99.
-
Moreth K, Frey H, Hubo M, Zeng-Brouwers J, Nastase MV, Hsieh LT, Haceni R, Pfeilschifter J, Iozzo RV, Schaefer L. Biglycan-triggered TLR-2- and TLR-4-signaling exacerbates the pathophysiology of ischemic acute kidney injury. Matrix Biol. 2014 Apr; 35:143-51.
-
Davies ML, Sei JJ, Siciliano NA, Xu RH, Roscoe F, Sigal LJ, Eisenlohr LC, Norbury CC. MyD88-dependent immunity to a natural model of vaccinia virus infection does not involve Toll-like receptor 2. J Virol. 2014 Mar; 88(6):3557-67.
-
Del Rosso JQ, Gallo RL, Tanghetti E, Webster G, Thiboutot D. An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and management of rosacea. Cutis. 2013 Mar; 91(3 Suppl):1-8.
-
Frey H, Schroeder N, Manon-Jensen T, Iozzo RV, Schaefer L. Biological interplay between proteoglycans and their innate immune receptors in inflammation. FEBS J. 2013 May; 280(10):2165-79.
-
Di Rosa M, Malaguarnera G, De Gregorio C, Palumbo M, Nunnari G, Malaguarnera L. Immuno-modulatory effects of vitamin D3 in human monocyte and macrophages. Cell Immunol. 2012 Nov; 280(1):36-43.